(INNF)
ASCRINVACUMAB(INNS)
ASKRINVAKUMAB(INNC)
IMMUNOGLOBULIN G2-KAPPA, ANTI-[HOMO SAPIENS ACVRL1 (ACTIVIN A RECEPTOR TYPE II-LIKE 1, ACTIVIN RECEPTOR-LIKE KINASE 1, ALK1, ALK-1, SERINE/THREONINE-PROTEIN KINASE RECEPTOR R3, SKR3, TRANSFORMING GROWTH FACTOR-BETA SUPERFAMILY RECEPTOR TYPE I, TGF-B SUPERFAMILY RECEPTOR TYPE I, TSR-I, HHT2, ORW2)], HOMO SAPIENS MONOCLONAL ANTIBODY; GAMMA2 HEAVY CHAIN (1-444) [HOMO SAPIENS VH (IGHV4- 31*02 (98.00%) -(IGHD) -IGHJ4*01) [10.7.10] (1-118) - IGHG2*01, G2M.. (CH1 (119-216), HINGE (217-228), CH2 (229-337), CH3 (338-442), CHS (443-444)) (119-444)], (132-215')-DISULFIDE WITH KAPPA LIGHT CHAIN (1'-215') [HOMO SAPIENS V-KAPPA (IGKV3-20*01 (99.00%) -IGKJ5*01) [7.3.9] (1'-108') -IGKC*01, KM3 (109'-215')]; DIMER (220- 220'':221-221'':224-224'':227-227'')-TETRAKISDISULFIDE, RECOMMENDED INN: LIST 75(WHO)
ASCRINVACUMABUM(INN)